Can trazodone (antidepressant) lower heart rate, particularly in patients with pre-existing cardiovascular conditions such as hypertension or heart failure?

Can Trazodone Lower Heart Rate?

Yes, trazodone tends to lower heart rate, though this effect is generally modest and occurs alongside more clinically significant cardiovascular risks including orthostatic hypotension and cardiac arrhythmias. 1

Cardiovascular Effects on Heart Rate

Trazodone produces a tendency toward heart rate reduction in most patients, distinguishing it from many other antidepressants that typically increase heart rate. 1 This bradycardic effect has been documented in multiple studies of depressed cardiac patients, where trazodone demonstrated little effect on cardiac conduction while producing less postural hypotension than most other antidepressants and tending to lower heart rate. 1

Documented Cases of Bradycardia

• A case report documented symptomatic bradycardia following a single 50 mg dose of trazodone in a patient with major depressive disorder, representing the first reported case of symptomatic bradycardia attributed to the lowest therapeutic dose. 2
• The bradycardia resolved upon discontinuation of the medication, suggesting a direct causal relationship. 2

Critical Cardiovascular Risks in Patients with Pre-existing Conditions

Primary Concerns Beyond Heart Rate

The American Heart Association recommends trazodone for insomnia in cardiovascular patients only after cognitive behavioral therapy has failed, due to significant cardiovascular risks. 3 These risks are particularly relevant for patients with hypertension or heart failure:

• Orthostatic hypotension is the most clinically significant cardiovascular effect, with trazodone users showing greater systolic BP drops immediately after standing (23.8 vs 14.3 mmHg, p=0.037) and diastolic drops (8.9 vs 1.6 mmHg, p=0.004). 4
• Cardiac arrhythmias represent a serious risk, though data suggest trazodone does not worsen supraventricular arrhythmias. 1, 3
• In hypertensive older adults (≥75 years), trazodone use was associated with a 58.3% incidence of syncope and falls compared to 21.2% in non-users (p=0.001). 4

Specific Contraindications

Avoid trazodone in patients with:

• Known QT prolongation 3
• Recent myocardial infarction 3
• Concurrent use of other QT-prolonging medications 3
• Pre-existing ventricular irritability (use with extreme caution, as two patients showed increased ventricular premature beats after starting trazodone) 1

Dosing Considerations for Cardiovascular Patients

Lower doses (100-300 mg daily) are better tolerated and more effective in patients with significant cardiovascular disease compared to higher doses. 1 The maximum tolerated dose in elderly patients is typically 300-400 mg/day, though younger patients may tolerate up to 600 mg/day. 5

Monitoring Requirements

Do not combine trazodone with antihypertensives or diuretics without careful monitoring, as this combination increases fall risk and hypotension severity. 3 Patients require:

• Baseline orthostatic vital signs before initiation
• Regular monitoring of blood pressure in both sitting and standing positions 4
• Assessment for symptoms of orthostatic hypotension (dizziness, lightheadedness, falls) 4
• Close monitoring for arrhythmias, particularly in patients with pre-existing cardiac conduction abnormalities 1, 5

Safer Alternatives for Cardiovascular Patients

Mirtazapine is considered a safer alternative to trazodone for cardiovascular patients, with demonstrated cardiovascular safety and additional benefits like appetite stimulation. 3 For depression specifically, sertraline represents the preferred SSRI due to minimal cardiovascular toxicity and lower QTc prolongation risk. 3

Clinical Bottom Line

While trazodone does lower heart rate, this bradycardic effect is overshadowed by more dangerous cardiovascular risks including severe orthostatic hypotension, arrhythmias, and dramatically increased fall risk in older adults with hypertension. 1, 4, 3 The heart rate reduction itself is generally not the primary clinical concern; rather, the combination of hypotensive effects and potential for cardiac arrhythmias makes trazodone a second-line choice in patients with cardiovascular disease, particularly those with hypertension or heart failure. 3, 1